Raymond James raises Fulgent Genetics stock price target to $36 on strong performance
Investing.com - BofA Securities raised its price target on Phibro Animal Health Corp. (NASDAQ:PAHC) to $32.00 from $27.00 while maintaining an Underperform rating on the stock. The current stock price of $43.04 sits just below its 52-week high of $44.35, reflecting the stock’s impressive 98.56% year-to-date return.
The price target increase reflects stronger demand for protein and improved profitability in the Livestock sector, along with lower costs for feed and grain inputs, which strengthens Phibro’s industry positioning, according to BofA Securities. InvestingPro data shows Phibro’s revenue grew 33.71% in the last twelve months, supporting this positive industry outlook.
Management expects the resurgence in protein demand to serve as a long-term tailwind for the company, continuing to grow alongside global population and income increases. This aligns with InvestingPro analysis indicating net income is expected to grow this year, though the stock currently trades at a relatively high P/E ratio of 36.12.
BofA Securities noted that livestock producers are investing more in animal health products, which should help sustain industry growth for Phibro.
The research firm also highlighted that the Livestock segment continues to deliver solid margins globally, with the company’s MFA (medicated feed additives) expansion helping to bolster its global presence further.
In other recent news, Phibro Animal Health Corporation reported impressive financial results for the first quarter of fiscal year 2026. The company announced earnings per share (EPS) of $0.73, which surpassed analyst expectations of $0.60. This represents a notable earnings surprise of 21.67%. Additionally, Phibro’s revenue reached $363.9 million, exceeding the projected $345.44 million. These results highlight a strong start to the fiscal year for Phibro. The earnings and revenue figures reflect positively on the company’s performance and have garnered attention from investors. Such robust financial performance may influence future analyst assessments and market perceptions. These developments underscore the company’s current trajectory in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.